Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectranetics to Hold 2013 Second Quarter Financial Results Conference Call on July 24

Spectranetics to Hold 2013 Second Quarter Financial Results Conference Call on July 24

COLORADO SPRINGS, Colo., July 11, 2013 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release 2013 second quarter financial results before market open on Wednesday, July 24, 2013. Company management will host an investment-community conference call beginning at 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time) on Wednesday, July 24 to discuss those results and to answer questions.

Individuals interested in listening to the conference call may do so by dialing (877) 561-2747 for domestic callers, or (973) 409-9689 for international callers, or from the webcast on the investor relations section of the Company's Web site at: www.spectranetics.com. The webcast will be available on the Company's Web site for 14 days following the completion of the call.

About Spectranetics

Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are sold in more than 40 countries and are used to treat arterial blockages in the heart and legs as well as the removal of pacemaker and defibrillator leads.

The Company's Vascular Intervention (VI) products include a range of peripheral and cardiac laser catheters for ablation of occluded arteries above and below the knee and within coronary arteries. The Company also markets aspiration and thrombectomy catheters for the removal of thrombus and support catheters to facilitate crossing of coronary and peripheral arterial blockages.

The Lead Management (LM) product line includes excimer laser sheaths and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads.

For more information, visit www.spectranetics.com.

CONTACT: COMPANY CONTACTS:
         Spectranetics Corporation
         Guy Childs, Chief Financial Officer
         (719) 633-8333
         
         INVESTOR CONTACTS:
         Westwicke Partners, LLC
         Lynn Pieper
         (415) 202-5678
         lynn.pieper@westwicke.com